Monitoring and Analysis of Chinese Chronic Myeloid Leukemia Patients Who Have Stopped Tyrosine Kinase Inhibitor Therapy

@article{Shen2019MonitoringAA,
  title={Monitoring and Analysis of Chinese Chronic Myeloid Leukemia Patients Who Have Stopped Tyrosine Kinase Inhibitor Therapy},
  author={Na Shen and Yong You and Zhao-dong Zhong and Li Meng and Jian-Feng Zhou and Ping Zou and Xiao-jian Zhu and Hong-xiang Wang and Fan-jun Cheng},
  journal={Current Medical Science},
  year={2019},
  volume={39},
  pages={211-216}
}
  • Na Shen, Yong You, +6 authors Fan-jun Cheng
  • Published in Current Medical Science 2019
  • Medicine
  • SummaryDiscontinuation of tyrosine kinase inhibitor (TKI) therapy after achieving a persistent deep molecular response (DMR) is an urgently needed treatment goal for chronic myeloid leukemia (CML) patients and has been included in the National Comprehensive Cancer Network (NCCN) guidelines (version 2.2017) for CML. Indeed, various studies have confirmed the feasibility of discontinuing TKI therapy. In this study, we analyzed data from 45 CML patients who had discontinued TKI therapy. Univariate… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 32 REFERENCES

    inhibitor therapy

    • PA Brown, B Shah, A Fathi
    • Br J Haematol,
    • 2018

    Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

    NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.